Structure-based virtual screening discovers potent and selective adenosine A1 receptor antagonists

Eur J Med Chem. 2023 Sep 5:257:115419. doi: 10.1016/j.ejmech.2023.115419. Epub 2023 May 1.

Abstract

Development of subtype-selective leads is essential in drug discovery campaigns targeting G protein-coupled receptors (GPCRs). Herein, a structure-based virtual screening approach to rationally design subtype-selective ligands was applied to the A1 and A2A adenosine receptors (A1R and A2AR). Crystal structures of these closely related subtypes revealed a non-conserved subpocket in the binding sites that could be exploited to identify A1R selective ligands. A library of 4.6 million compounds was screened computationally against both receptors using molecular docking and 20 A1R selective ligands were predicted. Of these, seven antagonized the A1R with micromolar activities and several compounds displayed slight selectivity for this subtype. Twenty-seven analogs of two discovered scaffolds were designed, resulting in antagonists with nanomolar potency and up to 76-fold A1R-selectivity. Our results show the potential of structure-based virtual screening to guide discovery and optimization of subtype-selective ligands, which could facilitate the development of safer drugs.

Keywords: Computer-aided drug design; G protein-coupled receptor; Molecular docking; Selectivity.

MeSH terms

  • Adenosine A2 Receptor Antagonists / chemistry
  • Adenosine A2 Receptor Antagonists / pharmacology
  • Adenosine*
  • Binding Sites
  • Ligands
  • Molecular Docking Simulation
  • Purinergic P1 Receptor Antagonists* / chemistry
  • Purinergic P1 Receptor Antagonists* / pharmacology
  • Receptor, Adenosine A1 / metabolism
  • Receptor, Adenosine A2A / metabolism

Substances

  • Purinergic P1 Receptor Antagonists
  • Ligands
  • Adenosine
  • Receptor, Adenosine A2A
  • Receptor, Adenosine A1
  • Adenosine A2 Receptor Antagonists